Status:
COMPLETED
Ustekinumab Plus UVB-311nm in Psoriasis
Lead Sponsor:
Medical University of Graz
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Ustekinumab, an IL-12/23 antibody has been approved in the E.C. and U.S.A. for the treatment of moderate to severe psoriasis. The aim of this study is to determine in a randomized half-side comparison...
Detailed Description
Patients with moderate to severe psoriasis who receive standard treatment with Ustekinumab (45 mg at week 0, 4, and every 12 weeks) are exposed to UVB-311nm phototherapy on a randomized body half (lef...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Psoriasis patients who receive treatment with Ustekinumab
Exclusion
- Age below 18 years
- Pregnancy or lactation
- History of malignant melanoma
- History of invasive squamous cell carcinoma of the skin
- Dysplastic melanocytic nevus syndrome
- Antinuclear antibodies (ds-DNA, Ro/SSA, La/SSB)
- Autoimmune disorders such as Lupus erythematosus or Dermatomyositis
- Photosensitive diseases such as porphyria, chronic actinic dermatitis, Xeroderma pigmentosum, basal cell nevus syndrome, and others
- General poor health status
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00870285
Start Date
March 1 2009
End Date
April 1 2011
Last Update
March 16 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University, Department of Dermatology
Graz, Austria, A-8036